Windtree Therapeutics (WINT) Misses Q1 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/19/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Appleās first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Brazil's Bolsonaro, Lula spar in first debate as personal attacks fly
- Yorkville Ives: 'GameStop Is Becoming the Hobby's Intake Network'
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Micron Technology stock drops on China chip news and labor dispute
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
Windtree Therapeutics Reports First Quarter 2016 Financial Results and Provides Business Updates
May 12, 2016 7:00 AM EDTWARRINGTON, Pa., May 12, 2016 /PRNewswire/ --Â Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today reported financial results for the first quarter ended March 31, 2016 and provided key business updates. The Company will also host a conference call today at 8:00 a.m. EDT.
Key Business and Financial Updates
Recently achieved an important milestone in the AEROSURF® phase 2b clinical trial in respiratory distress syndrome (RDS) with the initiation of sites and enrollment at selected clinical sites in... More


